Teva Pharma Free Cash Flow Over Time
| TEVA Stock | USD 17.12 0.04 0.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Teva Pharma Performance and Teva Pharma Correlation. Teva |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Analysis
Compare Teva Pharma Industries and related stocks such as Haleon plc, Bausch Health Companies, and Zoetis Inc Free Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HLN | 543 M | 543 M | 543 M | 543 M | 543 M | 543 M | 543 M | 543 M | 543 M | 543 M | 1.1 B | 1.1 B | 1.7 B | 1.4 B | 1.3 B |
| BHC | (2.4 M) | 290.5 M | 475.4 M | 857 M | 1.8 B | 1.9 B | 1.8 B | 2 B | 1.3 B | 1.2 B | 802 M | 1.1 B | (996 M) | 760 M | 566.3 M |
| ZTS | (37 M) | 362 M | 328 M | 497 M | 431 M | 440 M | 497 M | 1.1 B | 1.5 B | 1.3 B | 1.7 B | 1.7 B | 1.3 B | 1.6 B | 947 M |
| TAK | 123.5 B | 274.7 B | 211.9 B | 69.8 B | 73.8 B | (59.4 B) | 149.3 B | 249.6 B | 194.4 B | 452 B | 774.5 B | 937.1 B | 343.5 B | 159.6 B | 292 B |
| ELAN | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | 45.6 M | 75.2 M | 352.8 M | 26.7 M | (351.9 M) | 286 M | 268 M | 117 M | 88.7 M |
| VTRS | 51.2 M | 440.6 M | 643.7 M | 772 M | 260.4 M | 1.1 B | 1.3 B | 1.2 B | 1.1 B | 1.4 B | 550.6 M | 2.5 B | 2.5 B | 2.3 B | 2.4 B |
| CTLT | 12.4 M | (16.3 M) | 15.2 M | 55.9 M | 30.8 M | 15.7 M | 159.7 M | 198 M | 29.6 M | (25.5 M) | (253 M) | (221 M) | (322 M) | (59 M) | (56 M) |
| SHPH | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (37.6 K) | (300.3 K) | (2.7 M) | (5.6 M) | (5.3 M) |
| LFCR | (4 M) | 16.8 M | 12.4 M | 6.2 M | 8.6 M | (19.1 M) | 6.7 M | (13.8 M) | (28.7 M) | (43.7 M) | (8.8 M) | (52.5 M) | (52.5 M) | (18.1 M) | (17.2 M) |
| TLRY | (43.1 K) | (43.1 K) | (41.2 K) | (6.4 M) | (6.4 M) | (4.2 M) | (46.3 M) | (172.4 M) | (193.3 M) | (191.9 M) | (83.6 M) | (211.3 M) | (12.9 M) | (60.2 M) | (63.2 M) |
| CGC | (7 K) | (18.7 K) | (37 K) | (2.4 M) | (21.7 M) | (23.2 M) | (56.6 M) | (259.7 M) | (1.2 B) | (1.5 B) | (639.9 M) | (593.9 M) | (568.1 M) | (285.9 M) | (300.2 M) |
| ACB | 15.1 K | (278.9 K) | (447.8 K) | (3 M) | (11.2 M) | (8.7 M) | (36.2 M) | (218.6 M) | (606.5 M) | (693 M) | (263.7 M) | (142.1 M) | (128 M) | (85.5 M) | (89.7 M) |
| SNDL | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (12.8 M) | (250.9 M) | (250.9 M) | (60.7 M) | (159.2 M) | (17.6 M) | (24.6 M) | (25.8 M) |
| CRON | (119.3 K) | (119.3 K) | (119.3 K) | (119.3 K) | (2.4 M) | (2.1 M) | (6 M) | (38.4 M) | (91.4 M) | (169 M) | (177.8 M) | (165.9 M) | (94 M) | (45.4 M) | (47.7 M) |
Teva Pharma Industries and related stocks such as Haleon plc, Bausch Health Companies, and Zoetis Inc Free Cash Flow description
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.My Equities
My Current Equities and Potential Positions
| Teva Pharma Industries | TEVA |
| Classification | Israel Wall Street |
| Location | Israel |
| Exchange | New York Stock Exchange |
USD 17.12
Check out Teva Pharma Performance and Teva Pharma Correlation. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Teva Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.